Mechanism of action and resistance to monoclonal antibody therapy

N Villamor, E Montserrat, D Colomer - Seminars in oncology, 2003 - Elsevier
Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with
hematological malignancies and autoimmune diseases. The most commonly employed …
被引用次数：115 相关文章

Mechanism of action and resistance to monoclonal antibody therapy.

N Villamor, E Montserrat, D Colomer - Seminars in Oncology, 2003 - europepmc.org
Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with
hematological malignancies and autoimmune diseases. The most commonly employed …

Mechanism of action and resistance to monoclonal antibody therapy

N Villamor, E Montserrat, D Colomer - Seminars in Oncology, 2003 - infona.pl
Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with
hematological malignancies and autoimmune diseases. The most commonly employed …

Mechanism of action and resistance to monoclonal antibody therapy

N Villamor, E Montserrat… - Seminars in …, 2003 - pubmed.ncbi.nlm.nih.gov
Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with
hematological malignancies and autoimmune diseases. The most commonly employed …

[引用][C] Mechanism of action and resistance to monoclonal antibody therapy

N VILLAMOR, E MONTSERRAT… - Seminars in …, 2003 - pascal-francis.inist.fr
Mechanism of action and resistance to monoclonal antibody therapy CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …

[引用][C] Mechanism of action and resistance to monoclonal antibody therapy

N VILLAMOR - Semin Oncol, 2003 - cir.nii.ac.jp

[引用][C] Mechanism of action and resistance to monoclonal antibody therapy

N VILLAMOR, E MONTSERRAT, D COLOMER - Seminars in oncology, 2003 - Elsevier